News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,454 Results
Type
Article (47913)
Company Profile (322)
Press Release (692209)
Multimedia
Podcasts (107)
Webinars (19)
Section
Business (209722)
Career Advice (2202)
Deals (36121)
Drug Delivery (125)
Drug Development (82660)
Employer Resources (194)
FDA (16564)
Job Trends (15333)
News (353719)
Policy (33434)
Tag
Academia (2750)
Academic (2)
Accelerated approval (23)
Adcomms (27)
Allergies (124)
Alliances (51153)
ALS (161)
Alzheimer's disease (1673)
Antibody-drug conjugate (ADC) (273)
Approvals (16729)
Artificial intelligence (488)
Autoimmune disease (117)
Automation (33)
Bankruptcy (367)
Best Places to Work (11831)
BIOSECURE Act (21)
Biosimilars (175)
Biotechnology (199)
Bladder cancer (144)
Brain cancer (52)
Breast cancer (593)
Cancer (4433)
Cardiovascular disease (366)
Career advice (1864)
Career pathing (38)
CAR-T (273)
CDC (51)
Celiac Disease (1)
Cell therapy (711)
Cervical cancer (35)
Clinical research (69756)
Collaboration (1513)
Company closure (4)
Compensation (1034)
Complete response letters (49)
COVID-19 (2777)
CRISPR (85)
C-suite (709)
Cystic fibrosis (136)
Data (5701)
Decentralized trials (2)
Denatured (40)
Depression (115)
Diabetes (458)
Diagnostics (6757)
Digital health (38)
Diversity (12)
Diversity, equity & inclusion (48)
Drug discovery (226)
Drug pricing (177)
Drug shortages (29)
Duchenne muscular dystrophy (212)
Earnings (90628)
Editorial (54)
Employer branding (25)
Employer resources (166)
Events (120187)
Executive appointments (967)
FDA (19317)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1367)
Gene editing (188)
Generative AI (42)
Gene therapy (558)
GLP-1 (962)
Government (4795)
Grass and pollen (6)
Guidances (376)
Healthcare (19244)
HIV (52)
Huntington's disease (42)
IgA nephropathy (77)
Immunology and inflammation (237)
Immuno-oncology (37)
Indications (75)
Infectious disease (3025)
Inflammatory bowel disease (183)
Inflation Reduction Act (16)
Influenza (101)
Intellectual property (213)
Interviews (349)
IPO (16834)
IRA (51)
Job creations (3854)
Job search strategy (1575)
Kidney cancer (15)
Labor market (85)
Layoffs (570)
Leadership (31)
Legal (8106)
Liver cancer (89)
Longevity (12)
Lung cancer (616)
Lymphoma (351)
Machine learning (38)
Management (63)
Manufacturing (689)
MASH (155)
Medical device (13843)
Medtech (13879)
Mergers & acquisitions (20253)
Metabolic disorders (1166)
Multiple sclerosis (145)
NASH (22)
Neurodegenerative disease (289)
Neuropsychiatric disorders (71)
Neuroscience (2780)
NextGen: Class of 2025 (6725)
Non-profit (4672)
Now hiring (61)
Obesity (550)
Opinion (271)
Ovarian cancer (151)
Pain (178)
Pancreatic cancer (191)
Parkinson's disease (257)
Partnered (31)
Patents (450)
Patient recruitment (390)
Peanut (55)
People (60580)
Pharmaceutical (73)
Pharmacy benefit managers (26)
Phase I (21733)
Phase II (30688)
Phase III (22884)
Pipeline (3787)
Policy (277)
Postmarket research (2644)
Preclinical (9499)
Press Release (72)
Prostate cancer (216)
Psychedelics (45)
Radiopharmaceuticals (267)
Rare diseases (722)
Real estate (6275)
Recruiting (76)
Regulatory (24392)
Reports (62)
Research institute (2532)
Resumes & cover letters (376)
Rett syndrome (23)
RNA editing (13)
RSV (75)
Schizophrenia (139)
Series A (225)
Series B (171)
Service/supplier (14)
Sickle cell disease (95)
Special edition (23)
Spinal muscular atrophy (156)
Sponsored (41)
Startups (3811)
State (2)
Stomach cancer (17)
Supply chain (100)
Tariffs (80)
The Weekly (65)
Vaccines (985)
Venture capital (76)
Weight loss (361)
Women's health (76)
Worklife (19)
Date
Today (120)
Last 7 days (583)
Last 30 days (2438)
Last 365 days (30829)
2025 (30116)
2024 (35959)
2023 (40865)
2022 (51928)
2021 (56503)
2020 (54901)
2019 (47648)
2018 (35942)
2017 (33098)
2016 (32678)
2015 (38782)
2014 (32378)
2013 (27541)
2012 (29798)
2011 (30537)
2010 (29032)
Location
Africa (813)
Alabama (79)
Alaska (7)
Arizona (297)
Arkansas (14)
Asia (40649)
Australia (6685)
California (10461)
Canada (3107)
China (984)
Colorado (443)
Connecticut (449)
Delaware (307)
Europe (88685)
Florida (1543)
Georgia (340)
Hawaii (3)
Idaho (62)
Illinois (798)
India (56)
Indiana (500)
Iowa (21)
Japan (366)
Kansas (124)
Kentucky (38)
Louisiana (25)
Maine (70)
Maryland (1321)
Massachusetts (7606)
Michigan (320)
Minnesota (604)
Mississippi (6)
Missouri (121)
Montana (30)
Nebraska (26)
Nevada (113)
New Hampshire (75)
New Jersey (2839)
New Mexico (30)
New York (2804)
North Carolina (1404)
North Dakota (10)
Northern California (5004)
Ohio (309)
Oklahoma (20)
Oregon (38)
Pennsylvania (2138)
Puerto Rico (19)
Rhode Island (45)
South America (1179)
South Carolina (58)
South Dakota (1)
Southern California (4046)
Tennessee (164)
Texas (1625)
United States (37607)
Utah (312)
Vermont (1)
Virginia (240)
Washington D.C. (83)
Washington State (857)
West Virginia (4)
Wisconsin (104)
Wyoming (2)
740,454 Results for "gilead sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes
Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology.
October 31, 2025
·
2 min read
·
Tristan Manalac
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV who are on complex treatment regimens, according to BMO Capital Markets.
November 14, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Gilead Sciences to Present at Upcoming Investor Conferences - November 4, 2025
November 4, 2025
·
1 min read
Press Releases
Gilead Sciences Announces Third Quarter 2025 Financial Results
October 31, 2025
·
21 min read
HIV
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries
In coordination with the United States President’s Emergency Plan for AIDS Relief, Gilead will make its twice-yearly HIV prophylactic Yeztugo available to resource-limited countries “at no profit.”
September 5, 2025
·
1 min read
·
Tristan Manalac
Earnings
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties
The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.
August 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
December 16, 2025
·
9 min read
Press Releases
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
September 30, 2025
·
3 min read
Press Releases
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
October 31, 2025
·
11 min read
Infectious disease
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership
The Global Fund to Fight AIDS, Tuberculosis and Malaria will work with Gilead and other private backers to ensure the HIV preventive Yeztugo, approved last month by the FDA, is available in low- and middle-income countries, concurrent with high-income nations.
July 10, 2025
·
2 min read
·
Tristan Manalac
1 of 74,046
Next
